TY - JOUR T1 - SARS-CoV-2 serological tests can generate false positive results for samples from patients with chronic inflammatory diseases JF - medRxiv DO - 10.1101/2020.11.13.20231076 SP - 2020.11.13.20231076 AU - Nastya Kharlamova AU - Nicky Dunn AU - Sahl K Bedri AU - Svante Jerling AU - Malin Almgren AU - Francesca Faustini AU - Iva Gunnarsson AU - Johan Rönnelid AU - Rille Pullerits AU - Inger Gjertsson AU - Karin Lundberg AU - Anna Månberg AU - Elisa Pin AU - Peter Nilsson AU - Sophia Hober AU - Katharina Fink AU - Anna Fogdell-Hahn Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/13/2020.11.13.20231076.abstract N2 - Objectives Patients with chronic inflammatory diseases are often treated with immunosuppressants and therefore are of particular concern during the SARS-CoV-2 pandemic. Serological tests will improve our understanding of the infection and immunity in this population, unless the tests give false positive results. The aim of this study was to evaluate the specificity of SARS-Cov-2 serological assays with samples from patients with chronic inflammatory diseases collected before April 2019, thus defined as negative.Methods Samples from patients with multiple sclerosis (MS, n=10), rheumatoid arthritis (RA, n=47) with or without rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (anti-CCP2) and RF +/- systemic lupus erythematosus (SLE, n=10), were tested with 17 commercially available lateral flow assays (LFA), two ELISA kits and one in-house developed multiplex bead-based assay.Results Six LFA and the in-house IgG assay gave the correct negative results for all samples. However, the majority of assays (n=13), gave false positive signal with samples from patients with RA and SLE. This was most notable in RF positive RA samples. MS samples did not give any false positive in any of the assays.Conclusion The majority of the verified serological assays were sensitive to interfering antibodies in samples from patients with chronic inflammatory diseases and therefore may have poor specificity in this context. For these patients, the risk of false positivity should be considered when interpreting results of the SARS-CoV-2 serological assays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Dr. Margaretha Nilssons Foundation for Medical Research, Vinnova (grant number 2020-02865) and the PCORI [Patient-Centered Outcomes Research Institute] contract MS-1511-33196 for Funded Research Project Standard CR8 with Karolinska Institutet for the project: Rituximab in Multiple Sclerosis: A Comparative Study on Effectiveness, Safety, and Patient-Reported Outcomes. Autoantibody analyses in EIRA was supported by grants from the Swedish Research Council, King Gustav V:s 80-year foundation, and the EU/EFPIA IMI project RTCure (grant no 777357). Autoantibody analyses in Bio-ADA cohort were supported by the grants from Professor Nanna Svartz Foundation, the Gothenburg Medical Society (GLS-889421) and the Regional agreement on medical training and clinical research between the Western Gotaland county council and the University of Gothenburg (ALFGBG-926621). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Review Authority in Stockholm and Gothenburg (2020 23/04, dnr 2020 01649, 2012/1550 31/3, dnr 96 174)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher. ER -